카바페넴계 항생제 시장 규모, 점유율 및 성장 분석 : 약제별, 적응증별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Carbapenem Based Antibiotics Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 1.91 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 5.12% during the forecast period (2026-2033).

The global carbapenem-based antibiotics market features key drugs such as imipenem, meropenem, ertapenem, and doripenem, primarily targeting multidrug-resistant Gram-negative infections. This market's growth is driven by the increasing prevalence of extended-spectrum B-lactamase (ESBL) producing pathogens that limit the efficacy of first-line treatments, leading clinicians to seek broader-spectrum alternatives. Hospital stewardship programs prioritize carbapenems for severe cases, influencing healthcare budgets. The rising demand for combination therapies to combat carbapenem-resistant Enterobacteriaceae (CRE) reinforces market expansion, as physicians increasingly pair carbapenems with B-lactamase inhibitors. Advances in AI-driven drug discovery further enhance this market by expediting the identification of new targets and optimizing treatment regimens, ensuring a sustained pipeline of effective therapies amid rising resistance challenges and fostering greater research investment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Carbapenem Based Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Carbapenem Based Antibiotics Market Segments Analysis

Global carbapenem based antibiotics market is segmented by drug, indication, distribution, end-user and region. Based on drug, the market is segmented into Imipenem-Cilastatin, Meropenem, Ertapenem, Doripenem and Biapenem. Based on indication, the market is segmented into Hospital-Acquired Pneumonia (HAP), Complicated Intra-Abdominal Infections and Septicemia. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Hospitals (ICU) and Specialty Infectious Disease Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics is being significantly propelled by the rising incidence of multidrug-resistant bacterial infections within hospital settings, leading clinicians to increasingly depend on these powerful treatment options. This growing reliance emerges from the urgent need for effective solutions to manage severe infections, resulting in heightened prescription rates, particularly in acute care environments. As medical professionals aim to reduce the risk of therapeutic failures, the market is responding with enhanced production and distribution of carbapenem antibiotics. This trend not only drives overall market growth but also underscores the critical role of carbapenems in improving treatment protocols and patient outcomes.

Restraints in the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics faces significant constraints primarily due to their high costs, which stem from intricate manufacturing processes and strict regulatory standards. These elevated prices present a substantial financial challenge for healthcare providers, particularly in resource-limited hospitals and emerging markets where budgetary constraints heavily influence procurement decisions. As a result, clinicians may turn to more affordable alternative therapies that offer similar efficacy, limiting market growth. Additionally, the financial burden affects patient adherence to outpatient treatments, reducing overall demand for carbapenem-based therapies across both public and private healthcare systems.

Market Trends of the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics is witnessing a significant upward trend driven by the rapid expansion of resistance surveillance initiatives in hospitals and laboratories. By adopting advanced genomic sequencing and real-time data platforms, healthcare providers are effectively monitoring the rise of carbapenem-resistant organisms. This proactive approach allows for timely adjustments in empiric therapy, curbing unnecessary carbapenem usage and enhancing regional antimicrobial stewardship efforts. Pharmaceutical companies are responding to these insights by focusing on the development of new candidates targeting specific resistance mechanisms, leading to increased demand for both established carbapenem products and innovative agents capable of combatting evolving resistance patterns.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Carbapenem Based Antibiotics Market Size by Drug & CAGR (2026-2033)

• Market Overview
• Imipenem-Cilastatin
• Meropenem
• Ertapenem
• Doripenem
• Biapenem

Global Carbapenem Based Antibiotics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Hospital-Acquired Pneumonia (HAP)
• Complicated Intra-Abdominal Infections
• Septicemia

Global Carbapenem Based Antibiotics Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Carbapenem Based Antibiotics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals (ICU)
• Specialty Infectious Disease Centers

Global Carbapenem Based Antibiotics Market Size & CAGR (2026-2033)

• North America (Drug, Indication, Distribution, End-User)
  • US
  • Canada
• Europe (Drug, Indication, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug, Indication, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug, Indication, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug, Indication, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co. (Primaxin/Imipenem)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Merrem/Meropenem)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Doribax)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (Tienam)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations